Literature DB >> 1494357

Comparative studies on the postantifungal effect produced by the synergistic interaction of flucytosine and amphotericin B on Candida albicans.

G M Scalarone1, Y Mikami, N Kurita, K Yazawa, M Miyaji.   

Abstract

A turbidometric method was used to measure Candida albicans yeast cell growth and to quantitate the postantifungal effect (PAFE) after exposure to various concentrations of flucytosine and amphotericin B, alone and in combination, for 2 hr at 30 degrees C. The drug concentrations used in the PAFE assays were determined by initial MIC and FIC (fractional inhibitory concentration) evaluations. The PAFE was calculated by the difference in time (hr) required for growth of the control and test cultures to reach the 0.5 absorbance level following removal of the drug by dilution. A synergistic PAFE was evidenced with combinations of the two drugs at concentrations below their individual MICs. Combinations of flucytosine (0.012 to 0.049 micrograms ml-1) and amphotericin B (0.195 to 0.39 micrograms ml-1) produced PAFEs ranging from 6.3 to 21.8 hr. These PAFEs persisted from 0.3 to 14.7 hr longer than those achieved when each of the two agents was assayed separately.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1494357     DOI: 10.1007/bf00436389

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  18 in total

1.  Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial.

Authors:  R A Larsen; M A Leal; L S Chan
Journal:  Ann Intern Med       Date:  1990-08-01       Impact factor: 25.391

Review 2.  Antifungal susceptibility tests.

Authors:  J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

3.  Growth kinetics of respiratory pathogens after short exposures to ampicillin and erythromycin in vitro.

Authors:  A U Gerber; W A Craig
Journal:  J Antimicrob Chemother       Date:  1981-11       Impact factor: 5.790

4.  Postantibiotic suppression of bacterial growth.

Authors:  R W Bundtzen; A U Gerber; D L Cohn; W A Craig
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

5.  A method for testing for synergy with any number of agents.

Authors:  M C Berenbaum
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

6.  Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro.

Authors:  F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

7.  Turbidometric characterization of the postantifungal effect: comparative studies with amphotericin B, 5-fluorocytosine and miconazole on Candida albicans.

Authors:  G M Scalarone; Y Mikami; N Kurita; Y Ichihara; K Yazawa; M Miyaji
Journal:  Mycoses       Date:  1991 Jul-Aug       Impact factor: 4.377

8.  Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis.

Authors:  A M Stamm; R B Diasio; W E Dismukes; S Shadomy; G A Cloud; C A Bowles; G H Karam; A Espinel-Ingroff
Journal:  Am J Med       Date:  1987-08       Impact factor: 4.965

9.  Treatment of murine invasive candidiasis with amphotericin B and cilofungin: evidence for enhanced activity with combination therapy.

Authors:  A M Sugar; L Z Goldani; M Picard
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

10.  The postantifungal effect of 5-fluorocytosine on Candida albicans.

Authors:  G M Scalarone; Y Mikami; N Kurita; K Yazawa; M Miyaji
Journal:  J Antimicrob Chemother       Date:  1992-02       Impact factor: 5.790

View more
  5 in total

Review 1.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  In vitro interaction between amphotericin B and azoles in Candida albicans.

Authors:  J A Vazquez; M T Arganoza; J K Vaishampayan; R A Akins
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

3.  Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation.

Authors:  Celeste Alvarez; David R Andes; Jeong Yeon Kang; Carmen Krug; Glen S Kwon
Journal:  Pharm Res       Date:  2017-02-15       Impact factor: 4.200

Review 4.  Antifungal combination therapy: clinical potential.

Authors:  John W Baddley; Peter G Pappas
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Postantifungal Effect of Antifungal Drugs against Candida: What Do We Know and How Can We Apply This Knowledge in the Clinical Setting?

Authors:  Nerea Jauregizar; Guillermo Quindós; Sandra Gil-Alonso; Elena Suárez; Elena Sevillano; Elena Eraso
Journal:  J Fungi (Basel)       Date:  2022-07-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.